02:25 AM EDT, 08/07/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our target price to USD49 from USD54, implying a 2025 P/E of 12.6x, a discount to its historical forward P/E average of 25x-31x, justified in our view to reflect increasing concern about its long-term competitive edge, but slightly above peer average of 12x to reflect NOVO's higher margin. Our EPADS estimates, which were lowered in July to reflect the guidance cut, remain unchanged. Share price continues to tumble after NOVO cut guidance for the second time this year in July as compounded GLP-1s and competition continue to hurt sales. Ozempic and Wegovy continued to be the main sales contributors in H1 2025, though both at growing at a much slower pace. Other challenges, including underwhelming results for CagriSema, as well as heightened competition, remain as risks to its long-term growth in our view.